Methods: Between October 2013 and August 2014, we prospectively enrolled 20 patients with catheter-related bloodstream infections (CRBSI) or CLABSI in three of our sister institutions in three countries including Brazil, Lebanon, and Japan. These patients received (M-EDTA-EtOH) lock therapy and were compared to 24 historical control patients who were matched based on organisms, underlying diseases and neutropenia status. The control patients had their CVCs removed and a new CVC inserted.
Results: The two groups had comparable clinical characteristics. In the lock therapy group 95% of the patients had microbiological eradication within 96 hours after starting lock therapy vs. 83% of the patients in the control group (p= 0.36). In the lock group, the CVC was salvaged and retained for a median of 21 days (range 7-51) from the onset of bacteremia whereas the CVC was removed after a median of 2 days in the control group (range 0-8 days. P<0.0001).
Conclusion: Our study suggests that M- EDTA-EtOH lock therapy seems to be an effective intervention to salvage long term CVCs in the setting of CLABSI/CRBSI in cancer and dialysis patients with limited vascular access.
R. Y. Hachem,
N. Hamerschlak, None
H. Saad, None
F. Ferraz Assir, None
N. Mori, None
Y. Jiang, None
F. Ghaly, None
A. M. Chaftari, None
I. Raad, Merck: Grant Investigator , Research grant
Allergan: Grant Investigator , Research grant
Infective Technologies, LLC: Co-Inventor of the Nitroglycerin-Citrate-Ethanol catheter lock solution technology which is owned by the University of Texas MD Anderson Cancer Center (UTMDACC) and has been licensed by Novel Anti-Infective Technologies, LLC in which Dr. Raad is a s and Shareholder , Licensing agreement or royalty